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Background: AHA/ACC guidelines recommend clopidogrel for secondary prevention of heart attack or stroke in patients with prior acute coronary 
syndrome (ACS). The purpose of this analysis was to evaluate real world usage of clopidogrel following hospitalization for ACS.
Methods: Patients were identified from a large US commercial claims database (MarketScan®). Eligible patients included those ≥18 years of 
age at the time of index ACS hospitalization between January 2007 and June 2008 and with continuous enrollment for 1 year before (baseline) 
and 2 years after (follow up) the index hospitalization. Post-discharge prescription antiplatelet agent use, including clopidogrel was assessed over 
2 years based on pharmacy claims. Aspirin use data were unavailable. A medication treatment gap of ≥ 30 days no supply was used to define 
discontinuation of treatment.
Results: Among 59,036 patients with an ACS hospitalization (mean age 64 years; 62% male), 51% had a myocardial infarction, 49% had unstable 
angina, 36% received a stent. Within 1 year prior to index ACS hospitalization, 17% of patients were on clopidogrel. During the 2-year follow-up 
period, 55% received clopidogrel, with 25% filling their first prescription within 30 days following discharge. Within 1 year of discharge, 55% of 
clopidogrel users continued the therapy, 29% discontinued at least once then re-started the therapy, and 16% discontinued the therapy completely. 
Over the 2-year period, 29% continued, 66% discontinued at least once then re-started, and 5% discontinued completely. The median time from 
index ACS discharge to first discontinuation was 402 days. Among the 21,078 patients with stent placement, 86% received clopidogrel, with 59% 
continuing therapy for ≥1 year and 32% continuing for at least 2 years. Among those without stent placement, 37% received clopidogrel, with 47% 
continuing for ≥1 year and 25% continuing for at least 2 years.
Conclusions: Despite current treatment guideline recommendations, clopidogrel use is suboptimal in patients following hospital discharge for an 
ACS-related event in a real world setting. More research is needed to minimize the gap.
